ArticleLipids in health and disease2025
Prevalence, correlates of dyslipidaemia, and 10-year cardiovascular risk among people living with HIV and people without HIV adults in Rwanda: insights from the NCOHIRWA cohort study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNoncommunicable diseases, primarily cardiovascular diseases (CVDs), are an emerging cause of morbidity in sub-Saharan Africa. Dyslipidaemia, a key modifiable CVD risk factor, is increasing but remains underdiagnosed and undertreated, particularly among people living with HIV (PLHIV), where HIV-related chronic inflammation, antiretroviral therapy (ART), and sociodemographic factors may contribute. This study assessed the prevalence, correlates of dyslipidaemia, and estimated 10-year CVD risk among PLHIV and people without HIV (PWoH) adults in Rwanda.
methodsWe analysed baseline data from 1,546 adults (1,234 PLHIV and 312 PWoH) enrolled in the NCOHIRWA Cohort from 12 Rwandan health facilities. Data were collected via standardised World Health Organisation (STEP) questionnaires. Dyslipidaemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, and 10-year CVD risk was calculated via the Framingham risk score. For group comparisons, chi-square tests were used. Multivariate logistic regression identified independent predictors of dyslipidaemia, with adjusted odds ratios and 95% confidence intervals reported.
resultsOverall, 979 participants (61.9%) had dyslipidaemia, with comparable prevalence rates among PLHIV (744/1234; 60.29%) and PWoH participants (205/312; 65.06%). The PWoH participants had higher LDL-C levels (59 (18.9%) vs. 120 (9.7%), p < 0.0001). Independent predictors of dyslipidaemia included female sex, older age, obesity, and widowhood. PLHIV had lower odds of having elevated total cholesterol (aOR = 0.68, 0.49-0.95). Based on the estimated 10-year CVD risk, 3.95% of the participants had high and 21.47% had very high 10-year CVD, respectively, which was concentrated among older, widowed women with low education levels.
conclusionDyslipidaemia and elevated CVD risk are highly prevalent among the study participants, with disparities based on HIV status, sex, and social vulnerability. Routine lipid screening and integrated HIV-CVD care, particularly for high-risk subgroups such as older women, are essential for reducing the long-term CVD burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.